Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196)
China
· Delayed Price · Currency is CNY 22.51
-0.31 (-1.36%)
Sep 6, 2024, 3:00 PM CST
Shanghai Fosun Pharmaceutical (Group) Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 1,834 | 2,386 | 3,731 | 4,729 | 3,663 | 3,322 | Upgrade
|
| Depreciation & Amortization | 2,358 | 2,920 | 2,336 | 1,804 | 1,633 | 1,436 | Upgrade
|
| Other Amortization | 746.74 | 199.12 | 111.69 | 144.79 | 95.37 | 84.64 | Upgrade
|
| Loss (Gain) From Sale of Assets | 7.64 | 7.56 | -125.6 | 15.42 | -5.71 | -17.73 | Upgrade
|
| Asset Writedown & Restructuring Costs | 20.24 | 29.03 | 200.48 | 321.01 | 10.11 | 89.98 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1,958 | -2,988 | -1,832 | -4,491 | -495.61 | -2,924 | Upgrade
|
| Stock-Based Compensation | 18.63 | 35.9 | 54.48 | 64.29 | 55.22 | 109.07 | Upgrade
|
| Provision & Write-off of Bad Debts | 91.33 | 110.36 | 62.18 | 72.85 | 79.68 | 86.09 | Upgrade
|
| Other Operating Activities | 1,939 | 1,796 | 1,067 | 1,021 | -1,053 | 1,532 | Upgrade
|
| Change in Accounts Receivable | 314.94 | 1,605 | -2,077 | -1,795 | -1,560 | -863.27 | Upgrade
|
| Change in Inventory | 321.04 | -333.91 | -1,430 | -464.75 | -1,253 | -505.19 | Upgrade
|
| Change in Accounts Payable | -1,772 | -2,208 | 2,307 | 2,467 | 1,529 | 883.57 | Upgrade
|
| Operating Cash Flow | 3,511 | 3,414 | 4,218 | 3,938 | 2,580 | 3,222 | Upgrade
|
| Operating Cash Flow Growth | -16.97% | -19.05% | 7.10% | 52.64% | -19.94% | 9.23% | Upgrade
|
| Capital Expenditures | -4,487 | -5,337 | -5,889 | -4,973 | -4,437 | -3,962 | Upgrade
|
| Sale of Property, Plant & Equipment | 14.75 | 9.01 | 107.13 | 97.1 | 8.88 | 33.98 | Upgrade
|
| Cash Acquisitions | 138.3 | -924 | -1,197 | -1,307 | -153.94 | -822.67 | Upgrade
|
| Divestitures | 134.35 | 0.3 | 709.21 | 1,688 | 13.6 | 3.88 | Upgrade
|
| Investment in Securities | -898.5 | 1,568 | 1,225 | 214.13 | -706.25 | 4,146 | Upgrade
|
| Other Investing Activities | 991.39 | 863.84 | 980.64 | 422.65 | 568.6 | 429.24 | Upgrade
|
| Investing Cash Flow | -4,107 | -3,819 | -4,064 | -3,857 | -4,706 | -171.96 | Upgrade
|
| Long-Term Debt Issued | - | 23,514 | 30,649 | 29,529 | 17,973 | 11,563 | Upgrade
|
| Long-Term Debt Repaid | - | -21,146 | -26,280 | -27,392 | -15,708 | -13,942 | Upgrade
|
| Net Debt Issued (Repaid) | 1,368 | 2,367 | 4,369 | 2,137 | 2,265 | -2,379 | Upgrade
|
| Issuance of Common Stock | - | - | 4,509 | - | - | - | Upgrade
|
| Common Dividends Paid | -2,495 | -2,455 | -2,374 | -1,914 | -1,835 | -1,864 | Upgrade
|
| Other Financing Activities | -518.93 | -1,249 | -2,076 | -1,043 | 1,037 | 2,307 | Upgrade
|
| Financing Cash Flow | -1,646 | -1,336 | 4,428 | -819.41 | 1,467 | -1,936 | Upgrade
|
| Foreign Exchange Rate Adjustments | 49.36 | 73.65 | 128.34 | -134.71 | -300.16 | -5.11 | Upgrade
|
| Net Cash Flow | -2,192 | -1,668 | 4,710 | -873.79 | -959.49 | 1,109 | Upgrade
|
| Free Cash Flow | -976.29 | -1,922 | -1,671 | -1,035 | -1,857 | -739.65 | Upgrade
|
| Free Cash Flow Margin | -2.41% | -4.64% | -3.80% | -2.65% | -6.13% | -2.59% | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.72 | -0.64 | -0.40 | -0.72 | -0.29 | Upgrade
|
| Cash Income Tax Paid | 2,229 | 2,378 | 1,609 | 1,837 | 2,196 | 2,275 | Upgrade
|
| Levered Free Cash Flow | -1,622 | -4,046 | -1,692 | -1,087 | -2,787 | -1,777 | Upgrade
|
| Unlevered Free Cash Flow | -727.64 | -3,218 | -1,089 | -572.47 | -2,236 | -1,105 | Upgrade
|
| Change in Net Working Capital | 249.55 | 1,776 | -159.78 | -802.09 | 1,219 | 260.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.